Title
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Phase
Phase 1Lead Sponsor
ArmaGen, IncStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Mucopolysaccharidosis IIIntervention/Treatment
agt-182 ...Study Participants
6AGT-182 is a fusion protein containing idursulfase that is intended to deliver the enzyme peripherally and to the brain, when administered intravenously. This study is a safety and dose ranging study to obtain safety and exposure data, as well as information on the biological activity of the investigational drug.
This is a sequential, open-label, dose escalation, multi-dose study in adults with Hunter syndrome. Two dose levels, assuming tolerability, are planned sequentially, with safety data from the previous cohort being reviewed prior to escalation to the next higher dose cohort. Subjects will receive weekly doses of AGT-182 for 8 weeks if ERT-naive or agreeing to a 6-week ERT washout, or for 13 weeks if currently taking ERT and not agreeing to washout.
Recombinant HIRMAb-IDS
AGT-182 solution for infusion will be administered intravenously at doses of 1.0 mg/kg or 3.0 mg/kg weekly for 8-13 weeks.
Inclusion Criteria: Male age 18 years or older Diagnosis of Hunter Syndrome (documented fibroblast or leukocyte IDS enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory - or any level of enzyme deficiency together with the presence of a pathogenic mutation in the IDS gene - and documentation of normal enzymatic activity of at least 1 other sulfatase.) Must fall into one of the following groups: currently receiving standard enzyme replacement therapy (ERT) and be willing to discontinue it for the study duration, taking AGT-182 instead have not received standard ERT for at least 3 months and have elevated uGAGs of at least 3.5 fold above age-related normals at study screening have never received ERT Voluntary written consent Sexually mature males must be advised to use a medically accepted method of contraception throughout the study. Exclusion Criteria: Refusal to complete screening/baseline evaluations Receipt of an investigational drug within the prior 90 days Any medical condition or other circumstances that may significantly interfere with study compliance Clinically significant spinal cord compression, evidence of cervical instability Known hypersensitivity to idursulfase or any of the components of AGT-182 Known to be nonresponsive to standard ERT treatment (i.e., high uGAG values despite taking full dose standard ERT) History of diabetes mellitus or hypoglycemia Contraindication to lumbar puncture, if the patient agrees to this optional assessment
